Syncom Formulations (India) Limited is a pharmaceutical company. The Company manufactures and markets over 300 pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoule injections and dry vial injections, dry syrups, ointments, inhalers and herbals. It exports various commodities, such as pharmaceutical, including active pharmaceutical ingredients (APIs) and surgical products; agro and confectionary products, including rice, wheat flour, chickpeas, soy de oiled cake, biscuits and candies, and industrial products, including fasteners, steel bars, roofing sheets and jute bags, and metal scrap. The Company's division, Cratus Life Care, is involved in taking care of domestic market's needs. Its antifungal products include Fluconazole Tablets 150 milligram (mg), Itrakonazole Tablets 100 mg, Furazolidone Capsules 100 mg and Itraconazole Capsules 100 mg. Its manufacturing facility is located at Pithampur, Madhya Pradesh.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.